stoxline Quote Chart Rank Option Currency Glossary
DURECT Corporation (DRRX)
1.74  -0.04 (-2.25%)    06-18 10:46
Open: 1.73
High: 1.79
Volume: 100,131
Pre. Close: 1.78
Low: 1.71
Market Cap: 54(M)
Technical analysis
2024-06-18 10:18:40 AM
Short term     
Mid term     
Targets 6-month :  2.19 1-year :  2.56
Resists First :  1.87 Second :  2.19
Pivot price 1.57
Supports First :  1.17 Second :  0.74
MAs MA(5) :  1.69 MA(20) :  1.49
MA(100) :  1.08 MA(250) :  1.83
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  79 D(3) :  73.7
RSI RSI(14): 67.9
52-week High :  5.34 Low :  0.46
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DRRX ] has closed below upper band by 11.0%. Bollinger Bands are 25.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.84 - 1.85 1.85 - 1.86
Low: 1.6 - 1.61 1.61 - 1.62
Close: 1.76 - 1.78 1.78 - 1.79
Company Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Headline News

Sun, 16 Jun 2024
Short Interest in DURECT Co. (NASDAQ:DRRX) Increases By 15.1% - MarketBeat

Sat, 15 Jun 2024
DURECT Co. (NASDAQ:DRRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Fri, 14 Jun 2024
Drug Manufacturers - Other Equities Technical Momentum -- DepoMed, Pernix Therapeutics Holdings, Novo Nordisk ... -

Fri, 14 Jun 2024
DURECT Corporation Announces Update on DUR-928 Development Program -

Tue, 14 May 2024
DURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call Transcript - Insider Monkey

Mon, 13 May 2024
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 31 (M)
Shares Float 30 (M)
Held by Insiders 5.9 (%)
Held by Institutions 22.5 (%)
Shares Short 913 (K)
Shares Short P.Month 928 (K)
Stock Financials
EPS -0.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.27
Profit Margin -279.8 %
Operating Margin -313 %
Return on Assets (ttm) -41.8 %
Return on Equity (ttm) -197 %
Qtrly Rev. Growth -11.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.26
EBITDA (p.s.) -1.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -32 (M)
Levered Free Cash Flow -27 (M)
Stock Valuations
PE Ratio -1.92
PEG Ratio -0.2
Price to Book value 6.61
Price to Sales 6.65
Price to Cash Flow -1.74
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android